Actively Recruiting
Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Led by Stuart Mazzone · Updated on 2024-05-09
31
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
S
Stuart Mazzone
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression in patients with chronic cough. The goal of this clinical trial is to investigate the effect of acute and prolonged administration of the drug Gefapixant on cough-related brain activity in patients with chronic cough. The main question it aims to answer is: does the mechanism of action of Gefapixant on the brainstem and brain circuits regulating cough differ between acute and prolonged therapy in people with chronic cough? Participants have their brain activity and their sensitivity to cough-inducing substances measured as well as complete questionnaires about their cough before and while taking daily Gefapixant.
CONDITIONS
Official Title
Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent to participate
- Be aged 18 to 65 years
- Be male or female
- Non-smoker for at least 5 years
- No history of neurological disease
- No acute respiratory infection within the past 8 weeks
- Have refractory or unexplained chronic cough lasting 1 year or more
- Have a self-reported cough severity of 40 mm or higher on a 10-point scale at screening
You will not qualify if you...
- Current smoker or recreational drug user
- Pregnant woman
- Contraindication to MRI scanning such as metal implants or claustrophobia
- Under 18 years old
- Intellectual or mental impairment
- Highly dependent on medical care
- Dependent or unequal relationship with any research team member
- Known allergy to chili
- Non-English speaker
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Melbourne
Parkville, Victoria, Australia, 3010
Actively Recruiting
Research Team
S
Stuart B Mazzone, PhD
CONTACT
T
Tara G Bautista, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here